Methylguanine DNA methyltransferase-mediated drug resistance-based selective enrichment and engraftment of transplanted stem cells in skeletal muscle

Stem Cells

Volumn 27, Issue 5, 2009, Pages 1098-1108

  Lee, Antonio S J ^a   Kahatapitiya, Prathibha ^a   Kramer, Belinda ^a   Joya, Josephine E ^b   Hook, Jeff ^a   Liu, Renjing ^b   Schevzov, Galina ^a,c   Alexander, Ian E ^a   McCowage, Geoff ^a   Montarras, Didier ^d   Gunning, Peter W ^a,c,e   Hardeman, Edna C ^b,e  

^a CHILDREN S HOSPITAL AT WESTMEAD   (Australia)

^b CHILDREN'S MEDICAL RESEARCH INSTITUTE   (Australia)

^c UNIVERSITY OF SYDNEY   (Australia)

^d INSTITUT PASTEUR   (France)

^e UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

Adult stem cells; CD34+; Muscle stem cells; Skeletal muscle; Stem cell transplantation; Tissue regeneration

Indexed keywords

6 O BENZYLGUANINE; ALKYLATING AGENT; CARMUSTINE; DNA METHYLTRANSFERASE; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; METHYLGUANINE DNA METHYLTRANSFERASE; NOTEXIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CD34 SELECTION; CELL ISOLATION; CELL NUCLEUS; CHEMOPROPHYLAXIS; CHEMOTHERAPY; CONTROLLED STUDY; DONOR SELECTION; DRUG MECHANISM; ENGRAFTMENT; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; MUSCLE FIBER MEMBRANE; MUSCLE REGENERATION; NONHUMAN; POLYMERASE CHAIN REACTION; QUANTITATIVE ANALYSIS; RECIPIENT; SKELETAL MUSCLE; STEM CELL TRANSPLANTATION; Y CHROMOSOME;

ANIMALS; ANIMALS, GENETICALLY MODIFIED; ANTIGENS, CD34; CARMUSTINE; CELL DIFFERENTIATION; CELL SEPARATION; CELL SURVIVAL; DRUG RESISTANCE; GUANINE; HUMANS; MICE; MUSCLE FIBERS, SKELETAL; MUSCLE, SKELETAL; MYOBLASTS; O(6)-METHYLGUANINE-DNA METHYLTRANSFERASE; REGENERATION; RETROVIRIDAE; STEM CELL TRANSPLANTATION; TRANSDUCTION, GENETIC;

MUS;

EID: 66149176910     PISSN: 10665099     EISSN: None     Source Type: Journal    
DOI: 10.1002/stem.28     Document Type: Article

References (65)

1. Bank A. Hematopoietic stem cell gene therapy: selecting only the best. J Clin Invest 2003;112:1478-1480. (Pubitemid 38056272)
2. Gerull S, Beard BC, Peterson LJ et al. In vivo selection and chemoprotection after drug resistance gene therapy in a nonmyeloablative allogeneic transplantation setting in dogs. Hum Gene Ther 2007;18:451-456.
3. Persons DA, Allay ER, Sawai N et al. Successful treatment of murine beta-thalassemia using in vivo selection of genetically modified, drug-resistant hematopoietic stem cells. Blood 2003;102:506-513. (Pubitemid 36841967)
4. Reese JS, Roth JC, Gerson SL. Bone marrow-derived cells exhibiting lung epithelial cell characteristics are enriched in vivo using methylguanine DNA methyltransferase-mediated drug resistance. Stem Cells 2008;26:675-681.
5. Podda S, Ward M, Himelstein A et al. Transfer and expression of the human multiple-drug resistance gene into live mice. Proc Natl Acad Sci U S A 1992;89:9676-9680.
6. Sorrentino BP, Brandt SJ, Bodine D et al. Selection of drug-resistant bone-marrow cells in vivo after retroviral transfer of human Mdr1. Science 1992;257:99-103.
7. Abonour R, Williams DA, Einhorn L et al. Efficient retrovirus-mediated transfer of the multidrug resistance 1 gene into autologous human long-term repopulating hematopoietic stem cells. Nat Med 2000;6:652-658. (Pubitemid 30398788)
8. Allay JA, Persons DA, Galipeau J et al. In vivo selection of retrovirally transduced hematopoietic stem cells. Nat Med 1998;4:1136-1143.
9. Cowan KH, Moscow JA, Huang H et al. Paclitaxel chemotherapy after autologous stem-cell transplantation and engraftment of hematopoietic cells transduced with a retrovirus containing the multidrug resistance complementary DNA (MDR1) in metastatic breast cancer patients. Clin Cancer Res 1999;5:1619-1628. (Pubitemid 29334437)
10. Hibino H, Tani K, Ikebuchi K et al. The common marmoset as a target preclinical primate model for cytokine and gene therapy studies. Blood 1999;93:2839-2848. (Pubitemid 29200774)
11. Licht T, Haskins M, Henthorn P et al. Drug selection with paclitaxel restores expression of linked IL-2 receptor gamma-chain and multidrug resistance (MDR1) transgenes in canine bone marrow. Proc Natl Acad Sci U S A 2002;99:3123-3128. (Pubitemid 34240596)
12. Moscow JA, Huang H, Carter C et al. Engraftment of MDR1 and NeoR gene-transduced hematopoietic cells after breast cancer chemotherapy. Blood 1999;94:52-61. (Pubitemid 29300134)
13. Persons DA, Allay JA, Bonifacino A et al. Transient in vivo selection of transduced peripheral blood cells using antifolate drug selection in rhesus macaques that received transplants with hematopoietic stem cells expressing dihydrofolate reductase vectors. Blood 2004;103:796-803. (Pubitemid 38129535)
14. Bowman JE, Reese JS, Lingas KT et al. Myeloablation is not required to select and maintain expression of the drug-resistance gene, mutant MGMT, in primary and secondary recipients. Mol Ther 2003;8:42-50. (Pubitemid 36939295)
15. Jansen M, Sorg UR, Ragg S et al. Hematoprotection and enrichment of transduced cells in vivo after gene transfer of MGMT(P140K) into hematopoietic stem cells. Cancer Gene Ther 2002;9:737-746.
16. Neff T, Horn PA, Peterson LJ et al. Methylguanine methyltransferase- mediated in vivo selection and chemoprotection of allogeneic stem cells in a large-animal model. J Clin Invest 2003;112:1581-1588. (Pubitemid 38056284)
17. Neff T, Beard BC, Peterson LJ et al. Polyclonal chemoprotection against temozolomide in a large-animal model of drug resistance gene therapy. Blood 2005;105:997-1002. (Pubitemid 40170867)
18. Ragg S, Xu-Welliver M, Bailey J et al. Direct reversal of DNA damage by mutant methyltransferase protein protects mice against dose-intensified chemotherapy and leads to in vivo selection of hematopoietic stem cells. Cancer Res 2000;60:5187-5195.
19. Sawai N, Zhou S, Vanin EF et al. Protection and in vivo selection of hematopoietic stem cells using temozolomide, O-6-benzylguanine, And An alkyltransferase-expressing Retroviral Vector. Mol Ther 2001;3:78-87.
20. Gerson SL. Selection without harm: Drug resistance gene therapy hits the big time. Blood 2005;105:914-1914
21. Pegg AE. Mammalian O-6-Alkylguanine-DNA alkyltransferase - Regulation and importance in response to alkylating carcinogenic and therapeutic agents. Cancer Res 1990;50:6119-6129. (Pubitemid 20323662)
22. Gerson SL. MGMT - Its role in cancer aetiology and cancer therapeutics. Nat Rev CA 2004;4:296-307. (Pubitemid 38525285)
23. Xu-Welliver M, Kanugula S, Pegg AE. Isolation of human O-6-alkylguanine-DNA alkyltransferase mutants highly resistant to inactivation by O-6-benzylguanine. Cancer Res 1998;58:1936-1945. (Pubitemid 28217470)
24. Davis BM, Koc ON, Gerson SL. Limiting numbers of G156A O-6-methylguanine-DNA methyltransferase-transduced marrow progenitors repopulate nonmyeloablated mice after drug selection. Blood 2000;95:3078-3084. (Pubitemid 30321157)
25. Cossu G, Sampaolesi M. New therapies for Duchenne muscular dystrophy: Challenges, prospects and clinical trials. Trends Mol Med 2007;13:520-526. (Pubitemid 350130348)
26. Morgan JE, Coulton GR, Partridge TA. Muscle precursor cells invade and repopulate freeze-killed muscles. J Muscle Res Cell Motil 1987;8:386-396.
27. Partridge T. Myoblast transplantation. Neuromuscul Disord 2002;12:S3-S6. (Pubitemid 36158764)
28. Partridge TA, Morgan JE, Coulton GR et al. Conversion of Mdx myofibers from dystrophin-negative to dystrophin-positive by injection of normal myoblasts. Nature 1989;337:176-179. (Pubitemid 19025378)
29. Huard J, Bouchard JP, Roy R et al. Human Myoblast transplantation - Preliminary-results of 4 cases. Muscle Nerve 1992;15:550-560.
30. Karpati G, Ajdukovic D, Arnold D et al. Myoblast transfer in duchenne muscular-dystrophy. Ann Neurol 1993;34:8-17.
31. Mendell JR, Kissel JT, Amato AA et al. Myoblast transfer in the treatment of duchennes muscular-dystrophy. N Engl J Med 1995;333:832-838.
32. Miller RG, Sharma KR, Pavlath GK et al. Myoblast implantation in Duchenne muscular dystrophy: The San Francisco study. Muscle Nerve 1997;20:469-478. (Pubitemid 27154638)
33. Tremblay JP, Malouin F, Roy R et al. Results of a triple blind clinical-study of myoblast transplantations without immunosuppressive treatment in young boys with Duchenne muscular-dystrophy. Cell Transplant 1993;2:99-112. (Pubitemid 23134486)
34. Fan Y, Maley M, Beilharz M et al. Rapid death of injected myoblasts in myoblast transfer therapy. Muscle Nerve 1996;19:853-860. (Pubitemid 26190645)
35. Skuk D, Roy B, Goulet M et al. Successful myoblast transplantation in primates depends on appropriate cell delivery and induction of regeneration in the host muscle. Exp Neurol 1999;155:22-30. (Pubitemid 29072601)
36. Skuk D, Goulet M, Roy B et al. Efficacy of myoblast transplantation in nonhuman primates following simple intramuscular cell injections: Toward defining strategies applicable to humans. Exp Neurol 2002;175:112-126. (Pubitemid 34507914)
37. Blau HM, Webster C. Isolation, characterization of human-muscle cells. Proc Natl Acad Sci U S A 1981;78:5623-5627.
38. Kramer BA, Lemckert FA, Alexander IE et al. Characterisation of a P140K mutant O6-methylguanine-DNA-methyltransferase (MGMT)-expressing transgenic mouse line with drug-selectable bone marrow. J Gene Med 2006;8:1071-1085. (Pubitemid 44480400)
39. Montarras D, Morgan J, Collins C et al. Direct isolation of satellite cells for skeletal muscle regeneration. Science 2005;309:2064-2067.
40. Hagstrom JE, Hegge J, Zhang G et al. A facile nonviral method for delivering genes and siRNAs to skeletal muscle of mammalian limbs. Mol Ther 2004;10:386-398. (Pubitemid 39117883)
41. Vlahovich N, Schevzov G, Nair-Shaliker V et al. Tropomyosin 4 defines novel filaments in skeletal muscle associated with muscle remodelling/ regeneration in normal and diseased muscle. Cell Motil Cytoskeleton 2008;65:73-85.
42. Muskiewicz KR, Frank NY, Flint AF et al. Myogenic potential of muscle side and main population cells after intravenous injection into sub-lethally irradiated mdx mice. J Histochem Cytochem 2005;53:861-873. (Pubitemid 40923462)
43. Schevzov G, Vrhovski B, Bryce NS et al. Tissue-specific tropomyosin isoform composition. J Histochem Cytochem 2005;53:557-570. (Pubitemid 40593969)
44. Le Fevre AC, Boitier E, Marchandeau JP et al. Characterization of DNA reactive and non-DNA reactive anticancer drugs by gene expression profiling. Mutat Res 2007;619:16-29. (Pubitemid 46602443)
45. Jefferies HBJ, Thomas G, Thomas G. Elongation factor-1-alpha messenger-RNA is selectively translated following mitogenic stimulation. J Biol Chem 1994;269:4367-4372. (Pubitemid 2046662)
46. Peault B, Rudnicki M, Torrente Y et al. Stem and progenitor cells in skeletal muscle development, maintenance, and therapy. Mol Ther 2007;15:867-877. (Pubitemid 46621645)
47. Qu-Petersen ZQ, Deasy B, Jankowski R et al. Identification of a novel population of muscle stem cells in mice: Potential for muscle regeneration. J Cell Biol 2002;157:851-864.
48. Sampaolesi M, Torrente Y, Innocenzi A et al. Cell therapy of alpha-sarcoglycan null dystrophic mice through intra-arterial delivery of mesoangioblasts. Science 2003;301:487-492. (Pubitemid 36900300)
49. Gussoni E, Soneoka Y, Strickland CD et al. Dystrophin expression in the mdx mouse restored by stem cell transplantation. Nature 1999;401:390-394. (Pubitemid 29454964)
50. Tidball JG. Inflammatory processes in muscle injury and repair. Am J Physiol Regul Integr Comp Physiol 2005;288:R345-R353. (Pubitemid 40129595)
51. Horn PA, Morris JC, Neff T et al. Stem cell gene transfer-efficacy and safety in large animal studies. Mol Ther 2004;10:417-431. (Pubitemid 39186106)
52. Neff T, Beard BC, Kiem HP. Survival of the fittest: In vivo selection and stem cell gene therapy. Blood 2006;107:1751-1760.
53. Kinoshita I, Vilquin JT, Guerette B et al. Very efficient myoblast allotransplantation in mice under Fk506 immunosuppression. Muscle Nerve 1994;17:1407-1415. (Pubitemid 24362813)
54. Wernig A, Zweyer M, Irintchev A. Function of skeletal muscle tissue formed after myoblast transplantation into irradiated mouse muscles. J Physiol (Lond) 2000;522:333-345. (Pubitemid 30068510)
55. Mimeault M, Hauke R, Batra SK. Stem cells: A revolution in therapeutics - Recent advances in stem cell biology and their therapeutic applications in regenerative medicine and cancer therapies. Clin Pharmacol Ther 2007;82:252-264. (Pubitemid 47260547)
56. Pituch-Noworolska A, Majka M, Janowska-Wieczorek A et al. Circulating CXCR4-positive stem/progenitor cells compete for SDF-1-positive niches in bone marrow, muscle and neural tissues: An alternative hypothesis to stem cell plasticity. Folia Histochem Cytobiol 2003;41:13-21. (Pubitemid 36215829)
57. Ratajczak M, Majka M, Kucia M et al. Expression of functional CXCR4 by muscle satellite cells and secretion of SDF-1 by muscle-derived fibroblasts is associated with the presence of muscle progenitors in bone marrow and hematopoietic progenitors in muscles: A new perspective on stem cell plasticity. Exp Hematol 2003;31:77-177
58. Collins CA, Olsen I, Zammit PS et al. Stem cell function, self-renewal, and behavioral heterogeneity of cells from the adult muscle satellite cell niche. Cell 2005;122:289-301. (Pubitemid 41032991)
59. Sacco A, Doyonnas R, Kraft P et al. Self-renewal and expansion of single transplanted muscle stem cells. Nature 2008;456:502-506. (Pubitemid 50278031)
60. Ferrari G, Cusella-De Angelis G, Coletta M et al. Muscle regeneration by bone marrow derived myogenic progenitors. Science 1998;279:1528-1530. (Pubitemid 28217075)
61. LaBarge MA, Blau HM. Biological progression from adult bone marrow to mononucleate muscle stem cell to multinucleate muscle fiber in response to injury. Cell 2002;111:589-601. (Pubitemid 35356563)
62. Luth ES, Jun SJ, Wessen MK et al. Bone marrow side population cells are enriched for progenitors capable of myogenic differentiation. J Cell Sci 2008;121:1426-1434.
63. Blau HM, Brazelton TR, Weimann JM. The evolving concept of a stem cell: Entity or function? Cell 2001;105:829-841.
64. Lagasse E, Shizuru JA, Uchida N et al. Toward regenerative medicine. Immunity 2001;14:425-436. (Pubitemid 32441595)
65. Chamberlain G, Fox J, Ashton B et al. Concise review: Mesenchymal stem cells: Their phenotype, differentiation capacity, immunological features, and potential for homing. Stem Cells 2007;25:2739-2749. (Pubitemid 350127858)